Antithrombosis drug Xarelto® set for success

The process of drug discovery is both time-consuming and expensive. Pharmaceutical research scientists nowadays combine chemistry with the latest automation technology. Bayer HealthCare’s development of the antithrombosis drug Xarelto® is a shining example of successful partnership between high-tech and classical chemistry. Our cover picture shows Bayer HealthCare employee Sandra Bilo with a high-throughput screening system. Each of the microtiter plates holds 1,536 test compounds, which the fully automated system investigates for biological activity. This is how promising drug candidates are identified for subsequent development into successful medicinal products. Read more about Xarelto® in the focus.